A Luteinizing Hormone-releasing Hormone Agonist for the Prevention of Chemotherapy-induced Ovarian Follicular Loss in Rats

Cancer Research

Volumn 45, Issue 8, 1985, Pages 3651-3656

  Ataya, Khalid M ^a   Weintraub, Alan M ^a   Clark, Martin R ^a   LeMaire, William J ^a   McKanna, James A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GONADORELIN; GONADORELIN DERIVATIVE;

ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; DRUG EFFICACY; ENDOCRINE SYSTEM; FEMALE GENITAL SYSTEM; HISTOPATHOLOGY; IN VITRO STUDY; NONHUMAN; OVARY; OVARY FOLLICLE; PRIORITY JOURNAL; RAT; THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; FEMALE; GONADOTROPIN-RELEASING HORMONE; LEUPROLIDE; OVARIAN FOLLICLE; RATS; RATS, INBRED STRAINS; TRIPTORELIN;

EID: 0021971690     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Anderson, K. E. and Kappas, A. Hormones and liver function. In: L Schiff and E. R. Schiff (eds.), Diseases of the Liver, pp. 167–235. Philadelphia: J. B. Lippincott Co., 1982.
2. Belohorsky, B., Siracky, J., Sandor, L., and Klauber, E. Comments on the development of amenorrhea caused by myleran in cases of chronic myelosis. Neoplasma, 7. 397–403,1960.
3. Blatt, J., Mulvihill, J., Ziegler, J., Young, R., and Poplack, D. Pregnancy outcome following cancer chemotherapy. Am. J. Med., 69:828–832,1980.
4. Burkl, W. and Schiechl, H. The growth of follicles in the rat ovary under the influence of busulphan and endoxan. Ceil Tissue Res., 186:351–359,1978.
5. Calabresi, P. and Parks, R. Antiproliferative agents and drugs used for immunosuppression. In: A. Goodman Gillman, L. S. Goodman, and A. Gillman (eds.), The Pharmacologic Basis of Therapeutics, pp. 1256–1313. New York: Macmillan Publishing Co., Inc., 1980.
6. Chapman, R. and Sutcliffe, S. Protection of ovarian funtion by oral contraceptive in women receiving chemotherapy for Hodgkin's disease. Blood, 58:849–851,1981.
7. Chapman, R. M., Sutcliffe, S. B., and Malpas, J. S. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA, 242: 1877–1881,1979.
8. Cusan, L., Auclair, C., Belanger, A., Ferland, L., Kelly, P., Seguin, C., and Labrie. F. Inhibitory effect of long-term treatment with a luteinizing hormone agonist on the pituitary-gonadal axis in male and female rats. Endocrinology, 104:1369–1376,1979.
9. DeVita, V. T., Jr., Lewis, B. J., Rozencweig, M., and Muggia, F. M. The chemotherapy of Hodgkin's disease: past experiences and future directions. Cancer (Phila.), 42: 979–990,1978.
10. DeVita, V. T., Jr., Simon, R. M., Hubbard, S. M., Young, R. C., Berard, C. W., Moxley, J. H. III., Frei, E. III., Carbone, P. P., and Canellos, G. P. Curability of advanced Hodgkin's disease with chemotherapy. Ann. Intern. Med., 92: 587–595,1980.
11. Dornfetd, E., Slater, D., and Scheffe, H. A method for accurate determination of volume and cell numbers in small organs. Anat. Rec., 82:255–259,1942.
12. Dubois, E. L., Horowitz, R. E., Weiner, J., Rosen, V., and Strain, L Cyclophosphamide in the treatment of systemic lupus erythematosus of mice and men. Arthritis Rheum., 11:477,1968.
13. Fosdick, W. M., Parsons. J. L., and Hill, D. F. Preliminary report: long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum., 11:151–161,1968.
14. Fries, J. F., Sharp, G. C., McDevitt, H. O., and Holman, H. R. Cyclophosphamide therapy in connective tissue disease. Clin. Res., 18:134,1970.
15. Glode, L. M., Robinson, J., and Gould, S. F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin releasing hormone. Lancet, /: 1132–1134,1981.
16. Goldenberg. R., Powell, R. Rosen, S. Marshall, J., and Ross, G. Ovarian morphology in women with anosmia and hypogonadotropic hypogonadism. Am. J. Obstet. Gynecol., 126:91–94,1976.
17. Hammond, C., Jelovsek, F., Lee, K., Creasman, W., and Parker, R. Effects of long-term estrogen replacement therapy. Am. J. Obstet. Gynecol., 733; 525–536,1979.
18. Hirshfield, A. and Midgtey, A. R. Morphometric analysis of follicular development in the rat. Biol. Reprod., 79: 597–605,1978.
19. Johnson, E., Gendrich, R., and White, W. Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin-releasing hormone agonist analog. Fertil. Stem., 27: 853–860.1976.
20. Jones, E. and Krohn, P. The effect of hypophysectomy as age changes in the ovaries of mice. J. Endocrinol., 21; 497–509,1961.
21. Kaplan, H. S. Hodgkin's Disease, Ed. 2, pp. 434–435, 474–475. Cambridge, MA: Harvard University Press, 1980.
22. Kumar. R., Biggart, J. D., McEvoy, J., and McGeown, M. Cyclophosphamide and reproductive function. Lancet, /: 1212–1214,1972.
23. Mattison, D., Chang, O., Thorgeirsson, S., and Shiromisu. K. The effects of cyclophosphamide, azathioprine, and 6-mercaptopurine on oocyte and follicle number in C57 BL/6N mice. Res. Comrnun. Chem. Pathol. Pharmacol., 31: 155–161.1981.
24. Meldrum, D., Tsao, Z., Monroe, S., Braunstein, G., Sladek, J., Lu, J., Vale. W., Rivier, J., Judd, H., and Chang, R. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J. Clin. Endocrinol. Metab., 58:755–757,1984.
25. Mietkiewski, K. and Fichna, P. Influence of endoxan on the rat testis. Folia Morphol. 32:445–455.1973.
26. Miller, J. and Cole, L. Changes in mouse ovaries after prolonged treatment with cyclophosphamide. Proc. Soc. Exp. Biol. Med., 733; 190–193,1970.
27. Miller, J. J., Williams, G. F., and Leissring, J. C. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am. J. Med., 50:530–535.1971.
28. Nelson, W., Steinberger, E., and Boccabella, A. Recovery of spermatogenesis in rats treated with nitrofurans. Anat. Rec., 118:333–334,1954.
29. Reddy, P. Azhar, S., and Menon, K. Multiple inhibitory actions of luteinizing hormone releasing hormone agonist on luteinizing hormone/human chorionic gonadotropin receptor-mediated ovarian responses. Endocrinology. 107; 930–936 1980.
30. Rivier, C., Rivier, J., and Vale, W. Chronic effects of [D-trp6-Pro9-NEt] luteinizing hormone releasing factor on reproductive processes in the female rat. Endocrinology, 103: 2299–2305,1978.
31. Uldall, P. R., Kerr, D. N. S. and Tacchi, D. Sterility and cyclophospriamide. Lancet,/; 693–694,1972.
32. Wame. G. L., Fairley, K. F., Hobbs. J. B. and Martin. F. I. Cyclophosphamide induced ovarian failure. N. Engl. J. Med. 289:1159–1162.1973.
33. West. C. D., Hong. R. and Holland. N. H. Effect of cyclophosphamide on lipoid nephrosis in the human and on aminonucleoside nephrosis in the rat. J. Pediatr., 68:516–524.1966.
34. Ying, S. and Guillemin. R. [D-Trp6-Pro9-NEt]-luteinizing hormone releasing hormone factor inhibits follicular development in hypophysectomized rats. Nature (Lond.), 280: 593–595,1979.